How does MAR002 compare to current acromegaly treatments?

MAR002 achieved greater and longer-lasting IGF-1 suppression compared to existing GHR antagonists.

What are Marea Therapeutics' key milestones for 2026?

Marea Therapeutics expects progress on MAR001 for cardiometabolic disorders and advancements in their siRNA program, alongside the MAR002 drug.

Home / Health / Marea's MAR002 Shows Strong IGF-1 Reduction in Trials

Marea's MAR002 Shows Strong IGF-1 Reduction in Trials

Q: What are the Phase I results for Marea Therapeutics' MAR002?

The Phase I study for MAR002 showed a favorable safety profile and significant, dose-dependent reductions in IGF-1, validating its mechanism of action.

14 Jan

•

Summary

MAR002 demonstrated significant, dose-dependent IGF-1 reduction.
Trial data shows MAR002 superior to current treatments.
Marea Therapeutics advances MAR001 and siRNA programs in 2026.

Marea's MAR002 Shows Strong IGF-1 Reduction in Trials

Marea Therapeutics has reported favorable top-line results from its initial Phase I study of MAR002, a novel antibody targeting the growth hormone receptor for acromegaly treatment. The trial, conducted in healthy volunteers, demonstrated a good safety profile and significant, dose-dependent reductions in IGF-1 levels.

Notably, MAR002 achieved over 45% IGF-1 suppression lasting up to 43 days at the highest dose, outperforming existing treatments in both magnitude and duration. This validates MAR002's mechanism and suggests suitability for bi-weekly or monthly dosing.

Looking ahead to 2026, Marea is advancing MAR001, a monoclonal antibody for cardiometabolic disorders, with Phase IIb study enrollment concluding by January 2026 and data expected mid-year. The company is also progressing a preclinical siRNA program targeting ANGPTL4, aiming for candidate nomination within the year.